ClosetInvestor, IMO, NP’s plan is to get ONE
Post# of 148158
(Total Views: 592)
Posted On: 10/02/2020 7:44:04 AM
Re: ClosetInvestor #59046
ClosetInvestor,
This is a possible scenario, however, once the drug is approved for one indication the dam will fall down and extended label or, better, off-label will be unstoppable. This was mentioned in the last Shareholders meeting (for label extension) and we have discussed it here before.
Please remember, Leronlimab is safe. Doctor will start prescribing, data will come, sales will increase ...
You now that rest of the drill.
We need ONE approval.
Quote:
IMO, NP’s plan is to get ONE approval and then sell the company. Right now, COVID and HIV are the only near term targets as neither cancer trial won’t complete until 2022, NASH hasn’t started and will take time to enroll, and even the potential Alzheimer’s trial will take time to enroll and complete. IMO, COVID could do it but no combo (because of Vyera and the barriers to combo market penetration aka Vyera).
This is a possible scenario, however, once the drug is approved for one indication the dam will fall down and extended label or, better, off-label will be unstoppable. This was mentioned in the last Shareholders meeting (for label extension) and we have discussed it here before.
Please remember, Leronlimab is safe. Doctor will start prescribing, data will come, sales will increase ...
You now that rest of the drill.
We need ONE approval.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼